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In t roduct ion
In the last number of years the expansion of scientific knowledge has resulted in the development of new treatments
and technologies. As Research Ethics Committees are among those at the forefront of ensuring that the scope and
nature of such advances occur in a safe and ethical manner, it is imperative that a formalised, exemplary process of
ethical review be in place. The development of codes of ethics related to research involving humans is comparatively
recent. The first international code of ethics for research involving human participants, the Nuremberg Code, 
was issued in 1947 and laid down standards for carrying out human experimentation, emphasising the subjects’
voluntary consent. In 1964 the World Medical Association took an important additional step by adopting the
Declaration of Helsinki, most recently revised in 2000, requiring that proposed experimentation on humans be
approved by a committee independent from the investigators conducting the research. The Belmont report was
published in the United States in 1979 and forms the basis of all US human research regulation. The report sets
forth the basic ethical principles underlying the acceptable conduct of research involving human participants. 
Those principles, respect for persons, beneficence, and justice, are now accepted as three essential requirements 
for the ethical conduct of research involving human participants. Most recently, the Council for International
Organisations of Medical Sciences (CIOMS), working with the World Health Organisation, issued a third edition of
biomedical research ethical guidelines in 2002 which feature recommendations on ethical review committees and 
the issue of safeguarding confidentiality. These documents demonstrate a trend towards making more explicit the
ethical standards that must be met if research on human beings is to be ethically acceptable. 
The regulations and recommendations contained within these international codes need to be adapted into
institutional operational guidance to be used at the local level to guide the planning, review, approval and conduct of
human research. In Ireland, the recent Regulations made by the Minister for Health and Children (Clinical Trials on
Medicinal Products for Human Use, S.I. No. 190 of 2004), the report of the Irish College of General Practitioners
entitled “Ethical questions to be considered by a research ethics committee when approving clinical trials which
involve genetic testing” (2003) and the Health Research Board’s report “Genetic Research and Human Biological
Samples: The Legal and Ethical Considerations” (2002) provide useful guidance in relation to ethical review of
clinical trials. However, Ireland currently lacks comprehensive guidance with respect to ethical review of research
involving human participants outside the remit of clinical trials. 
4
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5This document is the result of systematic evaluation and analysis of international best practice (see list of
Supporting Documents) and comprehensive discussion undertaken by a working group of the Irish Council for
Bioethics. It is based on requirements for ethical review established in international guidelines and provides
guidance on general standards and principles that should be considered by Research Ethics Committees when
reviewing research proposals. This guidance is intended to facilitate and support efficient and effective ethical
review of proposals. This document should be viewed as a basis upon which Research Ethics Committees can
establish and develop their standard operating procedures. 
Impartial ethical review is designed to maintain ethical standards of practice in research, to protect participants 
in research and research workers from harm or exploitation, to preserve the subject's rights, including the right to
privacy and to provide reassurance to the public that all of this is being done. In promoting these goals Research
Ethics Committees should be mindful that appropriately regulated, ethically acceptable, rigorous research benefits
society as a whole. The primary task of Research Ethics Committees is the protection of the welfare and the rights
of participants in research. Another important role is to facilitate and support the progress that the research
community seeks to achieve. 
The Council is hopeful that the guidance contained in this document will facilitate Research Ethics Committees
in conducting independent, comprehensive, ethical review of research proposals, which will serve investigators and
the public alike. 
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6Sect ion  1  :  Pr inc ip les  o f  E th ica l  Rev iew
Research involving human participants should be based on a fundamental moral commitment to the individuals
concerned and to advancing human welfare, knowledge and understanding. A number of guiding moral principles
govern the ethical review of research proposals, which aim to protect the well-being and rights of research
participants/volunteers. 
Research involving human participants should be based on a fundamental moral commitment to the individuals
concerned and to advancing human welfare, knowledge and understanding. A number of guiding moral principles
govern the ethical review of research proposals. These principles aim to protect the well-being and rights of research
participants/volunteers. 
1.1 Respect for Persons
Respect for persons is expressed as regard for the welfare, rights, beliefs, perceptions, and customs, both individual
and collective, of individuals involved in research. Respect for persons is most commonly manifested through the
exercise of informed consent, which requires that people’s beliefs and opinions be respected, and that they be
allowed to choose for themselves whether or not they wish to participate in research. In order to choose they must 
be informed of their options, including the possible risks and benefits of those options. They must be assured of the
necessity of the research, including the fact that all possible risks have been minimised, and, where significant risk 
is involved, that no other method of research is possible. They must be asked to make their choice in circumstances,
which are free of coercion or undue pressure, and they must be free to withdraw from the research process at any
time. This decision must not affect their health care in any way. Ethical review should focus on the entire process 
of obtaining consent, not just on the written consent documents, but on how participants are informed of the study, 
who discusses it with them, and in what circumstances. The requirement for free and informed consent presumes
that adequate information is provided to obtain an informed judgement, that information provided is in a form and
delivered in a manner that will enable it to be understood and that the consent is voluntary in nature.
In the research context, respect for persons requires that limitations to an individual’s autonomy are recognised and that
appropriate mechanisms are in place to protect against abuse, exploitation or discrimination. Of particular concern here
are children, individuals with an intellectual disability or with short or long-term unconsciousness. Parental or guardian’s
consent must be sought, but such consent can only be accepted where the research in question is clearly in the best
interests of the subject concerned, or where the research concerned carries minimal risk or impact on the subject
concerned.
6
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71.2 Privacy and Confidentiality
Privacy and confidentiality are an integral part of the protection and promotion of human dignity and help to protect
and maintain a person’s mental or psychological well-being. The need for research should be weighed against
infringements of privacy and steps must be taken to ensure that individuals are protected from any harm that might
be caused as the result of access to their personal information.
1.3 Validity of Research Proposals
The scientific merit of a study is itself an ethical issue. The essential features of ethically justified research involving
human participants are that the research offers a means of developing information, not otherwise obtainable, that the
design of the research is scientifically sound, that the investigators and other research personnel are qualified and
capable and that the methods to be used should be appropriate to the objectives of the research and the field of study. 
1.4 Risks
As research involves advancing the frontiers of knowledge, its undertaking usually involves a degree of uncertainty
about the precise magnitude of and kind of benefits and harms that attend proposed research. The principle of
beneficence requires that researchers maximise the potential benefits to the participants and minimise the potential
risks of harm. If there are any risks resulting from participation in the research, then there must be benefits, either to
the subject, or to humanity or society in general. The principle of non-maleficence requires that researchers ensure
that predictable injury, either through acts of commission or omission, will be prevented.
1.5 Justice
Justice imposes duties to neither neglect nor discriminate against individuals or groups who may benefit from
advances in research, to avoid imposing on a particular group an unfair burden of participation in research and to
design research so that the selection and recruitment of research participants/volunteers is fair. Justice requires also
that the research be responsive to the health conditions or needs of vulnerable participants. In such cases there must
be clear and unambiguous justification for the research and for its application to such participants, and normally
there should be potential for direct health-related benefit to the subject, or the absence of any significant risk or
discomfort. 
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Sect ion  2  : Research  Requ i r ing  E th ics  Rev iew
All Research involving or impacting upon human participants requires ethics review by a research ethics committee,
before the research is started, except as stipulated below. 
For the purposes of this guidance, Research is defined as a systematic investigation to establish facts, principles or
knowledge and a study of some matter with the objective of obtaining or confirming knowledge.
2.1 Specific activities that may require REC review
Specific activities that may require REC review include, but are not necessarily limited to the following:
(a) Clinical trials involving human participants 
(b) New treatment or interventions
(c) Research involving human remains, cadavers, tissues, discarded tissue (e.g. placenta), biological fluids 
(d) Physiological studies
(e) Comparing an established procedure, whether therapeutic, non-therapeutic or diagnostic, with other procedures
which are not recognised as established by virtue of their recent development, discovery or use in a new or
unfamiliar way
(f) Innovative practices in health and disability services
(g) Research conducted by students, which includes all activities that meet the definition of research with human
participants
(h) Observational clinical research
(i) Access to personal information by means of questionnaires, interviews or other techniques of information
gathering
(j) Research involving the secondary use of data (use of data not collected for that research purpose), if any form of
identifier is involved and/or if health information pertaining to individuals is involved
(k) Case studies, when a series of subject observations allow possible extrapolation of generalisation of the results
from the reported cases and when there is an intent to publish or disseminate the data
Note to item 2.1(g) above: As supervised student research is conducted primarily for the purpose of educating
students on research techniques and methodologies, REC should review research protocols with a view to
contributing to the students’ education concerning scientific and ethical principles governing research.
8
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92.2 Activities that may not require REC review
Review by REC may not be required for:
(a) Research utilising existing publicly available documents or data 
(b) Observational studies in public places in which the identity of the participants remains anonymous
(c) Case study of one patient with the proviso that written informed consent has been obtained from the relevant
subject
(d) Quality assurance studies
(e) Audits 
The opinion of the REC should be sought whenever there is any doubt about the applicability of this guidance to a
particular research project.
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Sect ion  3  :  Research  Eth ics  Commit tees
3.1 Constituting a Research Ethics Committee 
A REC should be constituted to ensure competent ethical review of research proposals submitted to the committee
and an independent and just review of any such proposals. The REC must define its mandate and authority and must
make clear the jurisdiction of the REC and its relationship to other relevant bodies or institutions. Institutions/
organisations under whose authority RECs are established must ensure that RECs have appropriate financial
(including indemnity arrangements for members of the committee) and administrative support to fulfil their function.
A publicly available standard operating procedure should be produced and RECs should act in accordance with their
operating procedures. 
3.2 Composition of a Research Ethics Committee
The guiding principle for appointing members to a REC is to ensure that the committee has the appropriate expertise,
skills, knowledge and perspectives to ensure an adequate and thorough ethics review. RECs should be
multidisciplinary and multi-sectoral in composition. Attention should be paid to age and gender balance. One third 
of the total membership should be lay members. The qualifications for lay members are independence from the
institution/organisation under whose authority the REC is established and their non-involvement in scientific, clinical
practice and legal work. Those who have no experience in professions associated with research on human beings are
more likely to bring a truly lay perspective. Committee members should elect a chairperson and a vice-chairperson. 
In general it would be advisable for a committee’s membership to include but not be restricted to the following:
(a) member(s) with knowledge of and current experience in the areas of research which are regularly considered 
by the REC (e.g. scientist).
(b) member(s) with knowledge of and current experience in the professional care, counselling or treatment of people
(e.g. nurse, medical practitioner, clinical psychologist, as appropriate)
(c) member(s) with training in ethics (e.g. ethicist, philosopher, theologian)
(d) member(s) with a qualification in law
(e) member(s) with training in statistics
(f) lay member(s)
10
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11
A minimum of seven members of the REC is required to be present at a meeting held to determine an opinion in
relation to an application to the REC. There should be a reasonable representation of members, which must include
the chairperson, or in his/her absence the vice-chairperson; a member with relevant clinical and/or methodological
expertise; a lay member and a member who is independent of the institution/organisation under whose authority the
REC is established.
A REC should have sufficient members to secure the minimum number of members required to determine an opinion
on an application. 
A REC may appoint a person to act as an alternate for each member of the committee, where the alternate satisfies
the same membership criteria as the member. The standard operating procedure of the REC should identify the
primary member for whom each alternate member may substitute. When alternates substitute for a primary member,
the alternate member should have received and reviewed the same material that the primary member received or
would have received. An alternate can only vote if the member for whom he/she acts as an alternate is absent. 
Where a chairperson or members of a REC believe there is insufficient expertise on the committee to assess an
application or an issue, the committee should seek additional expert advice. Experts may have specialist knowledge
in particular fields of science or medicine or they may be representatives of communities or special interest groups.
Co-opted expert members are not entitled to vote.
3.3 Appointment of Members of a Research Ethics Committee
Clear procedures should be formulated to identify and appoint members to RECs. These should include:
(a) procedures for selecting candidates
(b) procedures for appointing members 
(c) name or description of person or institution responsible for making appointments
(d) duration of an appointment
(e) policy for renewal of an appointment
(f) procedure for replacing members
(g) procedure for resignation of a member
(h) procedure for the disqualification of a member
(i) training of members
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Note to item 3.3(a) above: When selecting candidates, the committee should take into account whether or not by
virtue of employment, profession or relationship, the candidate could be construed to have a potential conflict of
interest with respect to a majority of proposals reviewed.
Note to item 3.3(b) above: appointing members should be by an open process. Vacancies should be advertised
publicly in the press and/or via local professional networks.
Note to item 3.3(d) above: Members should be appointed for a fixed term, which may be renewed, but should not
normally exceed two consecutive terms on the same REC. The benefit of maintaining some continuity of membership
by overlapping terms of office should be considered.
3.4 Duties and responsibilities of a Research Ethics Committee Member
(a) Committee members have a commitment to protect and safeguard the rights and interests of human participants
participating in research, while promoting and facilitating research excellence.
(b) A member should be prepared to have his/her name, profession and affiliation published. 
(c) Members are expected to treat as confidential all applications, meeting deliberations, information on research
participants/volunteers and related matters. 
(d) When a committee member believes they have a conflict of interest on a subject which will compromise their
ability to make an impartial decision, they should declare that conflict of interest and withdraw themselves from
the discussion and/or activity.
(e) A member is expected to attend at least two-thirds of all scheduled REC meetings in each year. Should a
member fail to do so, the chairperson should address this with the member concerned.
(f) A member must agree to take part in education and ongoing training appropriate to his or her role as a REC
member.
12
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Sect ion  4  : Submi t t ing  an  app l i ca t ion
RECs have the responsibility of establishing well-defined submission procedures for research proposals, which are
readily available to prospective applicants.
4.1 Application Procedure
An application for ethics committee review in respect of proposed research must be made in writing and signed by a
qualified researcher responsible for the conduct of the study. This will usually be the chief investigator. Material to be
submitted as part of an application may include but is not restricted to:
(a) the name(s) and address(es) of the REC members to whom the application is to be submitted.
(b) the application forms
(c) the documentation required
(d) the format for submission
(e) the number of copies to be submitted
(f) the deadline for submission of the application
(g) the means by which applications will be acknowledged, including the communication of an incomplete
application
(h) the expected time for notification of the decision following review
(i) the fee structure, if any, for reviewing an application
(j) the application procedure for amendments to the proposal, the recruitment material, the potential research
participation information, or the informed consent form
(k) the information given to research participants/volunteers and the appropriate safeguards for the protection of
personal data
4.2 Documentation
The applicant should submit all documentation required for a thorough and complete ethical review of the proposed
research. The applicant should be aware of the elements of the review process (see 5.2) and submit the necessary
documentation to conduct this review. The REC should advise all applicants on documentation required for review. 
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This may include but is not restricted to:
(a) a signed and dated application form
(b) the protocol of the proposed research (clearly identified and dated), together with supporting documents and
appendices
(c) a summary, synopsis or diagram (‘flowchart’) in non-technical language
(d) a description of the ethical considerations involved in the research
(e) case report forms, diary cards, and other questionnaires intended for research participants/volunteers
(f) when the research involves the study of a product (such as a pharmaceutical or device under investigation) an
adequate summary of all pharmacological and toxicological data available on the product, together with a
summary of clinical experience with the product to date (e.g. recent investigator’s brochure, a summary of the
product’s characteristics) should be included
(g) current curriculum vitae of the applicant(s) (updated, signed and dated)
(h) material used (including advertisements) for participant/volunteer recruitment
(i) patient/volunteer information
(j) a full description of the process to obtain and document consent 
(k) suitable arrangements for indemnifying participants/volunteers and investigators 
(l) all significant previous decisions (e.g. those leading to a negative decision or modified proposal) by other RECs
or regulatory authorities for the proposed research (whether in the same location or elsewhere) and an indication
of the modification(s) to the protocol made on that account. The reasons for previous negative decisions should
be provided.
14
BioEthics_A4_ReadPair  8/7/04  10:31 AM  Page 15
15
Sect ion  5  : Rev iew procedure
All properly submitted and valid applications shall be reviewed in a timely fashion and according to an established
review procedure described in the REC’s standard operating procedures. A valid application is one which has been
submitted by an appropriate investigator, is complete, with all the necessary documents attached, and is signed and
dated.
Under the Clinical Trials on Medicinal Products for Human Use Regulations 2004 RECs are required to give an
opinion on research protocols involving standard products, no more than 60 days after acknowledgement of receipt
of a “valid” application has been received. Where research involves gene therapy, somatic cell therapy or genetically
modified organisms RECs are required to make a decision no more than 90 days after acknowledging that a “valid”
application has been received. Where external consultation is deemed necessary RECs are permitted a total of 180
days to make a decision following acknowledgement of receipt of a “valid” application. There are no time limits
imposed on RECs making a decision on research involving xenogenic cell therapy.
5.1 Meeting Requirements
RECs should meet in accordance with regularly scheduled dates. Meeting requirements should include the following:
(a) meetings should follow a previously scheduled agenda
(b) members should be given sufficient time to review relevant documentation
(c) meetings should be minuted. There should be an approval procedure for the minutes
(d) when appropriate, the sponsor and/or investigator may be invited to present the proposal to the members and
answer any questions a committee may have
(e) when appropriate, independent experts (e.g. researchers with specific competence, ethicists, statisticians) may
be invited to attend
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5.2 Elements of Review
When reviewing research proposals a REC should consider the following:
Scientific design and conduct of the study
(a) the appropriateness of the study design in relation to the objectives of the study, the statistical methodology
(including sample size calculation) and the potential for reaching reliable conclusions with the smallest number 
of research participants/volunteers
(b) the justification of predictable risks and inconveniences weighed against the anticipated benefits for the research
participants/volunteers and the concerned communities
(c) the justification for use of control arms in trials (whether placebo or active comparator), and the randomisation
programme to be used
(d) criteria for withdrawing participants/volunteers prematurely
(e) criteria for suspending or terminating research 
(f) the adequacy of conditions made for the monitoring and auditing the conduct of the research
(g) the adequacy of the site including the supporting staff, facilities and emergency procedures
(h) the form in which the results will be reported and published
Recruitment of research participants/volunteers
(a) the characteristics of the population from which the participants/volunteers will be drawn (including gender, age,
ethnicity) and the justification for any decisions made in this regard
(b) the method by which initial contact and recruitment are to be conducted
(c) the method by which information is to be conveyed to participants/volunteers or their representatives and by
which means consent is to be obtained
(d) inclusion and exclusion criteria for research participants/volunteers
Care and protection of research participants/volunteers
(a) the safety of any intervention to be used in the proposed research
(b) the suitability of the investigator for the proposed research in relation to his/her qualifications and experience
(c) any plans to withdraw or withhold standard therapies or clinical management protocols for the purpose of the
research, and the justification for such action
16
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(d) the adequacy of health and social supervision and psychological support for the research participants/volunteers
(e) the adequacy of medical supervision and follow-up concerning the participants/volunteers
(f) steps to be followed if participants/volunteers decide to withdraw during the course of the research
(g) the arrangements, if appropriate, for informing the participant’s/volunteer’s GP, including procedure for seeking
consent to do so
(h) a description of any scheme to make the study product available to the participants/volunteers following the
research
(i) a report of the expenses (if any) payable to participants/volunteers 
(j) the provisions for compensation/treatment in the case of the injury/disability/death of a participant/volunteer
connected to participation in the study
(k) the provisions made for receiving and responding to queries and complaints of participants/volunteers throughout
the course of the study
(i) the insurance and indemnity agreements covering the liability of the investigator by the sponsor
(l) a description of any grants, payments or other reward to be made to any researchers or research hosts
(m) a description of possible conflicts of interest which might affect the independent judgement of the researcher(s)
Protection of confidentiality of participants/volunteers 
(a) a description of the persons who will have access to personal data of the participant/volunteer including medical
records and biological samples
(b) a description of provisions to ensure the confidentiality and security of personal information concerning
participants/volunteers
(c) the extent to which the information will be anonymised
(d) how samples/data will be obtained, and the purposes for which they will be used
(e) how long samples/data will be kept
(f) to which countries (if any) the samples/data will be sent
Both REC members and investigators should be aware of the provisions of the Data Protection Acts 1988 and 2003
and their obligations as set out in those Acts. 
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Informed consent process
(a) description of the procedures for obtaining informed consent, including the identification of those responsible for
obtaining consent and the time frame in which it will occur
(b) the adequacy, comprehensiveness and understandability of written and oral information given to the participants/
volunteers, their relatives/guardians and, if necessary, their legal guardians
(c) the content and wording of the informed consent form and, when applicable, the provisions made for
participants incapable of giving consent personally
(d) clear justification for the intention to include participants/volunteers who cannot consent and a full account of the
arrangements for obtaining consent or authorisation for the participation of such individuals
(e) description of the procedures for disclosure, if appropriate, of relevant information to participants/volunteers
which may become available during the study
Community considerations
(a) the impact and relevance of the research on the local community and on the concerned communities from which
the participants/volunteers are drawn
(b) a description of procedures to consult with the concerned communities during the course of designing the
research
(c) the extent to which the research contributes to e.g. the enhancement of local healthcare, research and the ability
to respond to public health needs
(d) a description of the availability and affordability of any successful study product to the concerned communities
following the research
(e) the manner in which the results of the research will be made available to participants/volunteers and the
concerned communities
5.3 Expedited Review
Where a REC wishes to incorporate expedited review into its standard operating procedures the following
specifications should be taken into account:
(a) the research should present minimal risk to participants/volunteers e.g. risks related to invasion of privacy and/or
breach of confidentiality
18
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(b) expedited review should be undertaken by the chairperson of the REC or by one or more experienced reviewers
i.e. REC members designated by the chairperson 
(c) reviewers may not disapprove research using expedited review. Research may only be disapproved in accordance
with non-expedited operational procedures
(d) each REC which uses expedited review must adopt a method for keeping all members informed of research
proposals which have been approved under this procedure
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5.4 Decision-making
A REC should ensure that all supporting documentation for an application is complete before coming to a decision on 
a research proposal. A REC should comply with a pre-defined method for arriving at a decision. It is recommended
that REC use the consensus model where the process of discussion and debate will lead to a decision, rather than a
formal vote-casting process. Under the consensus model, the proposal will be approved when all members present
are willing to allow the proposal to proceed. In cases in which consensus seems unlikely, the chairperson may call for
a vote with a two-thirds majority required for approval. Dissenting members should be afforded the opportunity to
append an opinion to the REC decision.
The REC should accommodate reasonable requests from investigators to participate in discussions about their
proposal, but may not be present when the REC is making its decision. 
It is desirable to adopt a consistent approach to granting or declining approval of a proposal. It is recommended that
the following terminology be used in communicating the decision of the REC to an applicant:
i. Approved, the applicant may conduct the research as outlined in the research proposal submitted to the REC
ii. Provisionally approved, subject to recommended revisions to the proposal or answers to questions posed to the
applicant. The revisions and/or answers must be resubmitted to the REC before receiving final approval. No
research may be conducted prior to receiving final approval.
iii. Approval declined detailed reasons for declining approval should be forwarded to the applicant, with or without
an invitation to resubmit a substantially altered proposal for reconsideration. 
The REC decision should be communicated to the applicant in writing within two weeks of the meeting at which the
decision was taken. The chairperson should sign and date all such communications. The decision is to include, but is
not limited to the following:
(a) project identification number and/or date of the proposal that the decision is based on
(b) exact title of proposal reviewed
(c) name and title of applicant
(d) name of REC taking the decision
(e) date and place of the decision
(f) chairperson and list of members present when decision was taken
(g) clear statement of the decision taken
20
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(h) terms and conditions, if any, of approval of proposal, with clearly defined reasons for such terms and conditions
(i) clearly stated reasons if approval has been declined
(j) whether approval was by expedited review
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Sect ion  6  : Procedures  fo r  mon i to r ing  ongo ing  research
REC should establish a review procedure for following the progress of all studies for which approval has been
granted. The review procedure should be specified in the standard operating procedure and should be clearly
communicated to investigators. 
6.1 Status report from investigators
On-going research should be subject to continuing ethics review. The frequency of such review should reflect the
degree of risk to participants in the research project. As a minimum the REC should require an annual report from
investigators on matters including:
(a) progress to date or outcome in the case of a completed project
(b) a statement of compliance with the approved proposal and/or amendments to the proposal
(c) a description of measures taken to maintain and secure personal information/records pertaining to the research
6.2 Amendments
Any significant alteration to a previously approved proposal must receive prior approval from the REC before
implementation. Significant alterations include changes to:
(a) personnel (including where work has been subcontracted to another investigator) any changes to named
researchers responsible for the conduct of the research; any change to the personnel involved in obtaining
informed consent or having access to personal information about research participants/volunteers
(b) method
(c) design of the study
(d) duration of the study
(e) informed consent procedures
(f) patient information leaflets
(g) method of recruitment
Under the Clinical Trials on Medicinal Products for Human Use Regulations 2004, the REC must, within a period of
35 days from the day of receipt of a valid notice of an amendment, furnish the applicant with an opinion. 
22
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6.3 Adverse Event
As a condition of approval of the research proposal the REC should require investigators to immediately report any
serious or unexpected adverse events on participants or unforeseen events that might affect the benefits/risks ratio of
the proposal. 
A serious adverse event is defined as any untoward medical occurrence that:
(a) results in death
(b) is life threatening
(c) requires in-patient hospitalisation or prolongation of existing hospitalisation
(d) results in persistent or significant disability/incapacity
(e) results in a congenital anomaly/birth defect
An unexpected event is an adverse reaction, the nature and severity of which is not consistent with the applicable
product information.
Investigators may take urgent safety measures to eliminate immediate jeopardy to the research participants/volunteers
prior to approval by the REC. However, investigators should provide the REC with a written report of any action taken 
at the earliest possible opportunity. The REC should review any new material and decide whether there are sufficient
grounds for changing its initial decision to grant approval to the proposal. 
Under the Clinical Trials on Medicinal Products for Human Use Regulations 2004, a written report of any urgent
safety measures taken should be submitted to the REC no later than three days from the date the measures were
taken.
6.4 Suspension or Termination of a Project
In the case of a premature suspension/termination of a study, the REC should require the investigator to inform the
REC of the reasons for premature suspension/termination. This should be accompanied by a summary of the results
obtained in the study up to the point of suspension/termination. The REC should require investigators to notify the
committee once a study has been completed. The REC should receive a final study report, summarising the main
findings.
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Under the Clinical Trials on Medicinal Products for Human Use Regulations 2004, the REC must be provided with a
detailed written explanation of the reasons for suspension or premature termination of a clinical trial within 15 days 
of the trial being halted. The REC must be provided with a written declaration of the end of the trial within 90 days.
End of the trial is defined as the date of the last visit of the last patient undergoing the trial. Suspension, termination 
or end of trial notification to the REC should be done using the Annex 3 form of the Community “Detailed guidance 
for the request for authorisation of a clinical trial on a medicinal product for human use to the competent
authorities, notification of substantial amendments and declaration of the end of the trial” (ENTR/CT 1). The REC
must receive within one year of the end of the trial a summary of the clinical trial report. The format of this
summary should comply as closely as possible with Annex 1 of the Community guideline on the Structure and
Content of Clinical Study Reports (CPMP/ICH/137/95).
24
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Sect ion  7  : Documenta t ion  & a rch iv ing
All documentation and communications of a REC should be dated, filed and archived according to provisions set out 
in the standard operating procedures. Documents must be stored in a secure place where there is adequate
protection against fire. A statement is required in the standard operating procedures defining the access and retrieval
procedures for documents, including details of who is authorised to access and/or retrieve REC documents.
Documents that should be filed and archived include, but are not limited to:
(a) written standard operating procedure
(b) annual reports
(c) curriculum vitae of each REC member
(d) record of all income and expenses of the REC, including expenses paid to REC members and co-optees
(e) guidelines on application procedures
(f) agendas of REC meetings
(g) minutes of REC meetings
(h) copies of all materials submitted by applicants
(i) correspondence by the REC concerning applicants, decisions and follow-up
(j) copies of decisions and any advice and/or requirements issued to applicants
(k) all written documentation received during follow-up
(l) notification of completion or premature suspension/termination of studies
(m) final study reports
Documents should be kept for a minimum of three years following notification of completion or premature
suspension/termination of a study.
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Sect ion  8  : Research  e th ics  commit tee  annua l  repor t
The REC should produce an annual report containing information relevant to its procedures including, 
but not limited to:
(a) membership/membership changes
(b) number and dates of meetings held
(c) attendance of members; confirmation of participation by required categories of members
(d) substantive changes to the standard operating procedures 
(e) list of training undertaken by members
(f) a list of proposals considered, the decision reached on each 
(g) time taken from acceptance of application to final decision on each proposal 
(h) list of projects completed or terminated during the year
Annual reports are public documents and should be available upon request.
26
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Sect ion  9  : Mul t i - cent re  s tud ies
Multi-centre studies may include research conducted at more than one institution or organisation, in one more
countries, either by the same or different investigators or research conducted jointly by investigators working with
different institutions or organisations. RECs should require investigators to indicate on application forms if a study is
being or has been reviewed by another REC and if so, the identity and decision of the REC.
In order to facilitate prompt and efficient review of multi-centre studies:
(a) An investigator may wish to distinguish between core elements of the research that cannot be altered without
invalidating the pooling of research data and those elements which can be altered to comply with local
requirements 
(b) RECs may wish to communicate with, give or receive advice from other RECs reviewing the proposal
(c) RECs may wish to accept a scientific assessment of the proposal from another REC
(d) RECs may agree to accept the conclusions of a single review committee
Note to item 9(c) above: A common scientific assessment could be produced by qualified members of a number of
RECs involved or by one REC which has accepted the role.
Note to item 9(d) above: A single committee could review the scientific and ethical aspects of a proposal. Individual
committees could verify the practicability of the proposal in the institution/ organisation and that the proposal
conforms to the ethos of the institution/organisation in which the research will be carried out. 
Under the Clinical Trials on Medicinal Products for Human Use Regulations 2004 in the case of multi-centre clinical
trials, either limited to sites in Ireland, or to sites located in more than one EU member state, a single ethics
committee opinion must be given by a recognised ethics committee and this opinion must prevail at all centres
where the trial is to be conducted. 
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approving clinical trials which involve genetic testing (2003).
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Report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.
Belmont report: ethical principles and guidelines for the protection of human subjects of research (1979) 
UNESCO (United Nations Educational, Scientific, Cultural Organization. Universal Declaration on the Human
Genome and Human Rights (1997).
World Health Organisation. Draft Operational Guidelines for Ethics Committees Reviewing Biomedical Research
(2000).
World Medical Association. Declaration of Helsinki: Recommendations Guiding Physicians in Biomedical Research
Involving Subjects (1964; 1975; 1983; 1989; 1996, 2000) 
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Work ing  Group on  Research  Eth ics  Commit tees
Professor Cecily Kelleher Chairperson
Dept. of Public Health Medicine and Epidemiology, University College Dublin
Dr. Margaret Fitzgerald Vice-Chairperson




Irish School of Ecumenics
Mr. Dan Lynch
Secretary to the Research Ethics Committee of St. James's Hospital and the Federated Dublin Voluntary Hospitals
Professor Anne Scott
School of Nursing, Dublin City University
Dr. Siobhán O’Sullivan
Irish Council for Bioethics
Terms of reference
1. To review in depth, the existing practices of Ethics Committees in the Republic of Ireland, with particular
reference to Research Ethics Committees.
2. To identify best practice in the area internationally and across the island of Ireland.
3. To produce guidance on the composition and operation of Ethics Committees and to suggest a national structure
for such organisations in the Republic of Ireland.
4. To report to Council on all aspects of the deliberations and conclusions of the working group on 
Ethics Committees.
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The I r i sh  Counc i l  f o r  B ioe th ics
Comhai r l e  B i the i t i ce  na  hÉ i reann
Mr Dermot Gleeson SC, MRIA Chairperson
Professor Peter Whittaker (Vice Chair) Institute of Environment, Philosophy and Public Policy at Lancaster University
Professor Patrick Cunningham, MRIA, Department of Genetics, Trinity College Dublin 
Mr Matt Dempsey, Irish Farmers' Journal 
Dr Dolores Dooley, Department of Philosophy, National University of Ireland, Cork 
Dr Margaret Fitzgerald, Department of Public Health, Eastern Regional Health Authority 
Dr Patrick Flanagan, formerly of Environmental Protection Agency 
Professor Patrick Hannon, St Patrick's College, National University of Ireland, Maynooth 
Mr. Kenneth Kearon, Irish School of Ecumenics 
Professor Cecily Kelleher, Department of Public Health, Medicine and Epidemiology, University College Dublin 
Professor Mark Lawler, Cancer Molecular Diagnostics Laboratory, St James' Hospital 
Professor Tony McGleenan, School of Law, University of Ulster 
Dr Peter McKenna, Department of Obstetrics and Gynaecology, Rotunda Hospital 
Ms Mary Mulvihill, Science Journalist 
Dr Nora O’Brien, Department of Food Science, Food Technology and Nutrition, National University of Ireland, Cork 
Professor Fergal O’Gara, Department of Microbiology, National University of Ireland, Cork
Professor Ronan O’Regan, MRIA, Department of Human Anatomy and Physiology, University College Dublin 
Professor Anne Scott, School of Nursing, Dublin City University 
Mr Asim Sheikh, BL, Division of Legal Medicine, University College Dublin
Professor Seán Strain, School of Biomedical Sciences, University of Ulster 
Secretariat
Dr Siobhán O’Sullivan, Scientific Director
Mr Pauric Dempsey
Ms Emily de Grae
Terms of Reference
1. To identify and interpret the ethical questions raised by biological and medical research in order to respond 
to and anticipate questions of substantive concern. 
2. To investigate and report on such questions in the interests of promoting public understanding informed
discussion and education. 
3. In the light of the outcome of its work, to stimulate discussion through conferences, workshops, lectures,
published reports and, where appropriate, suggest guidelines. 
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